Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Htlv-1 Vaccination Landscape: Current Developments and Challenges Publisher



Letafati A1, 2 ; Bahari M2, 3 ; Salahi Ardekani O2 ; Nayerain Jazi N2 ; Nikzad A4 ; Norouzi F2 ; Mahdavi B2 ; Aboofazeli A2 ; Mozhgani SH5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Virology, Faculty of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Research Center for Clinical Virology, Tehran University of Medical Science, Tehran, Iran
  3. 3. Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  4. 4. Dipartimento di Chimica Organica e Industriale, Universita’ di Milano, Milan, Italy
  5. 5. Department of Microbiology and Virology, Alborz University of Medical Science, Alborz, Iran

Source: Vaccine: X Published:2024


Abstract

Human T-lymphotropic virus type 1 (HTLV-1) is a retrovirus that is distinguished for its correlation to myelopathy/tropical spastic paraparesis (HAM/TSP) and adult T-cell leukemia/lymphoma (ATLL). As well, HTLV-1 has been documented to have links with other inflammatory diseases, such as uveitis and dermatitis. According to the World Health Organization (WHO), the global distribution of HTLV-1 infection is estimated to extend between 5 and 10 million individuals. Recent efforts in HTLV-1 vaccine development primarily involve selecting viral components, such as antigens, from structural and non-structural proteins. These components are chosen to trigger a vigorous immune response from cytotoxic T lymphocytes (CTLs), helper T lymphocytes (HTLs), and B cells. Investigation into developing a vaccine against HTLV-1 is ongoing, and current surveys have explored several approaches, including viral vector vaccines, DNA vaccines, protein and peptide vaccines, dendritic cell-based vaccines, mRNA vaccines, and other platforms. Despite these investigations have shown promising results, challenges like the necessity for long-term protective immunity, addressing viral diversity, and managing potential side effects remain. It is critical to keep track of the progress made in HTLV-1 vaccination research to comprehend the development status and its possible impacts. The evolving nature of vaccine development underscores the importance of staying informed about advancements as we strive to combat HTLV-1-associated diseases through effective vaccination strategies. In this review, our goal is to provide an overview of the current status of HTLV-1 vaccination efforts, emphasizing the progress, challenges, and potential future directions in this vital area of research. © 2024 The Author(s)